QUINTESSENTIAL

This trial is seeking approximately 150 participants. Participants will receive BMS-986393, an investigational, autologous CAR T-cell therapy. 

Participants will start the process of receiving BMS-986393 by undergoing a process called leukapheresis. This means that T cells will be removed from their blood and changed in a laboratory to become the investigational CAR T-cell therapy, BMS-986393. During the time that BMS-986393 is being manufactured, participants will receive mandatory bridging therapy. 

These investigational BMS-986393 CAR T-cells are then given back by intravenous infusion. Before receiving investigational BMS-986393, participants will receive a conditioning regimen of chemotherapy over three days. 

Participants may be hospitalized while receiving BMS-986393 or may receive investigational BMS-986393 at a qualified outpatient center depending on the investigators discretion. Participants will need to be closely monitored after receiving investigational BMS-986393. Patients will need to stay within a 30-minute transportation ride to the study site for at least 7 days and then within 120-minute transportation ride to the site and have a dedicated full-time caregiver or caregivers until 1 month after the investigational BMS-986393 infusion. 
[arm1]